Methods of treating mesothelioma by administration of compounds comprising FGFR1 ECD
AssigneesFive Prime Therapeutics, Inc., Glaxosmithkline Intellectual Property (No.2) Limited
InventorsDavid Bellovin, Kevin Baker, Thomas Brennan, Arundathy Nirmalini Pandite, Bijoyesh Mookerjee, Maurice P. DeYoung, Rakesh Kumar
Life of this patent
Estimating the term…
Abstract
Methods of treating cancers comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule are provided. Methods of treating cancers comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule and at least one anti-angiogenic agent are provided.
Claims19
A method of treating mesothelioma comprising administering to a human subject with mesothelioma an effective amount of a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) or FGFR1 ECD fusion molecule and at least one therapeutic agent selected from paclitaxel, carboplatin, docetaxel, pemetrexed, and cisplatin, wherein the mesothelioma has a higher level of fibroblast growth factor 2 (FGF2) mRNA compared to vascular endothelial growth factor (VEGF) mRNA or a higher level of FGF2 protein compared to VEGF protein.
Dependencies are inferred from the claim text.